Data from the phase Ib/II CARTITUDE-1 trial that were presented at the 2019 ASH Annual Meeting demonstrated the anti-BCMA CAR T-cell therapy JNJ-4528 achieved a 100% overall response rate with responses in 29 patients with heavily pretreated relapsed/refractory multiple myeloma.
Panelists discuss the presentation and management of a case involving metastatic non–-small cell lung cancer (NSCLC) with a ROS1 alteration, focusing on treatment approaches and…
Bexobrutideg, a first-in-class Bruton’s tyrosine kinase degrader, has been granted orphan drug designation from the FDA in Waldenström macroglobulinemia.
Panelists discuss how RATIONALE-305 trial data shows promising updated overall survival benefits for patients receiving tislelizumab plus chemotherapy compared to placebo plus chemotherapy in advanced…
Orca-T improved 1-year survival without severe graft-vs-host disease compared with standard transplant in the Precision-T study.
During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for chronic lymphocytic leukemia.
An expert discusses how treatment selection for first-line (1L) tyrosine kinase inhibitor (TKI) therapy in advanced hepatocellular carcinoma (HCC) requires careful evaluation of multiple factors,…
The first patient has been enrolled in the PROSTATE-IQ trial of ArteraAI, a multimodal artificial intelligence biomarker test.
A panelist discusses how managing adverse events associated with TKIs and belzutifan requires a proactive approach encompassing prevention strategies, regular monitoring, dose modifications when needed…
Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.
Panelists discuss the presentation and management of a case involving metastatic non–-small cell lung cancer (NSCLC) with a ROS1 alteration, focusing on treatment approaches and…
